According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The ...

Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...